83 related articles for article (PubMed ID: 8764187)
1. Effects of glucagon-like peptide-I on glucose turnover in rats.
Van Dijk G; Lindskog S; Holst JJ; Steffens AB; Ahrén B
Am J Physiol; 1996 Jun; 270(6 Pt 1):E1015-21. PubMed ID: 8764187
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.
Larsson H; Holst JJ; Ahrén B
Acta Physiol Scand; 1997 Aug; 160(4):413-22. PubMed ID: 9338524
[TBL] [Abstract][Full Text] [Related]
3. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
4. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.
Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk FW; Holst JJ; Rizza RA
Diabetes; 2001 Mar; 50(3):565-72. PubMed ID: 11246876
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.
Hvidberg A; Nielsen MT; Hilsted J; Orskov C; Holst JJ
Metabolism; 1994 Jan; 43(1):104-8. PubMed ID: 8289665
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic.
Freyse EJ; Knospe S; Becher T; El Hag O; Göke B; Fischer U
Metabolism; 1999 Jan; 48(1):134-7. PubMed ID: 9920158
[TBL] [Abstract][Full Text] [Related]
7. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.
Burcelin R; Da Costa A; Drucker D; Thorens B
Diabetes; 2001 Aug; 50(8):1720-8. PubMed ID: 11473030
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo.
Hargrove DM; Nardone NA; Persson LM; Andrews KM; Shepherd KL; Stevenson RW; Parker JC
Metabolism; 1996 Mar; 45(3):404-9. PubMed ID: 8606650
[TBL] [Abstract][Full Text] [Related]
9. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
D'Alessio DA; Vogel R; Prigeon R; Laschansky E; Koerker D; Eng J; Ensinck JW
J Clin Invest; 1996 Jan; 97(1):133-8. PubMed ID: 8550824
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats.
Hendrick GK; Gjinovci A; Baxter LA; Mojsov S; Wollheim CB; Habener JF; Weir GC
Metabolism; 1993 Jan; 42(1):1-6. PubMed ID: 8446036
[TBL] [Abstract][Full Text] [Related]
11. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration.
Hargrove DM; Nardone NA; Persson LM; Parker JC; Stevenson RW
Metabolism; 1995 Sep; 44(9):1231-7. PubMed ID: 7666800
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
13. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
14. Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats.
Iritani N; Sugimoto T; Fukuda H; Komiya M; Ikeda H
J Nutr; 1999 Jan; 129(1):46-50. PubMed ID: 9915874
[TBL] [Abstract][Full Text] [Related]
15. Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs.
Kawai K; Suzuki S; Ohashi S; Mukai H; Murayma Y; Yamashita K
Acta Endocrinol (Copenh); 1990 Dec; 123(6):661-7. PubMed ID: 2284891
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.
Tolessa T; Gutniak M; Holst JJ; Efendic S; Hellström PM
J Clin Invest; 1998 Aug; 102(4):764-74. PubMed ID: 9710445
[TBL] [Abstract][Full Text] [Related]
17. Glucose metabolism during exercise in man: the role of insulin in the regulation of glucose utilization.
Lavoie C; Ducros F; Bourque J; Langelier H; Chiasson JL
Can J Physiol Pharmacol; 1997 Jan; 75(1):36-43. PubMed ID: 9101063
[TBL] [Abstract][Full Text] [Related]
18. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.
Zhao T; Parikh P; Bhashyam S; Bolukoglu H; Poornima I; Shen YT; Shannon RP
J Pharmacol Exp Ther; 2006 Jun; 317(3):1106-13. PubMed ID: 16489128
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat.
Bozkurt A; Näslund E; Holst JJ; Hellström PM
Regul Pept; 2002 Jul; 107(1-3):129-35. PubMed ID: 12137975
[TBL] [Abstract][Full Text] [Related]
20. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
